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Abstract
The main genetic determinant of soluble IL-6R levels is the missense variant rs2228145, which 
maps to the cleavage site of IL-6R. For each Ala allele, sIL-6R serum levels increase by ~20 
ng/ml and asthma risk by 1.09-fold. However, this variant does not explain the total heritability for 
sIL-6R levels. Additional independent variants in IL6R may therefore contribute to variation in 
sIL-6R levels and influence asthma risk. We imputed 471 variants in IL6R and tested these for 
association with sIL-6R serum levels in 360 individuals. An intronic variant (rs12083537) was 
associated with sIL-6R levels independently of rs4129267 (P = 0.0005), a proxy SNP for 
rs2228145. A significant and consistent association for rs12083537 was observed in a replication 
panel of 354 individuals (P = 0.033). Each rs12083537:A allele increased sIL-6R serum levels by 
2.4 ng/ml Analysis of mRNA levels in two cohorts did not identify significant associations 
between rs12083537 and IL6R transcription levels. On the other hand, results from 16 705 
asthmatics and 30 809 controls showed that the rs12083537:A allele increased asthma risk by 
1.04-fold (P = 0.0419). Genetic risk scores based on IL6R regulatory variants may prove useful in 
explaining variation in clinical response to tocilizumab, an anti-IL-6R monoclonal antibody.
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Introduction
Asthma is a chronic lung disease characterized by airway obstruction, inflammation and 
hyperresponsiveness.1 It is caused by a combination of both genetic and environmental 
factors but their interaction is complex and still not fully understood.
IL-6 is a cytokine known to be involved in allergic asthma2–5 and it binds to its target cells 
through a complex of at least two distinct membrane-bound proteins, an 80 kD ligand 
binding glycoprotein (IL-6R) and a 130 kD signal transducing glycoprotein (gp130).6, 7 
Although gp130 is expressed on most cells, expression of the membrane-bound form of 
IL-6R (mIL-6R) is limited to hepatocytes and some immune cells, such as neutrophils, 
monocytes, CD4+ T cells and B cells;8, 9 as such, only these cells are directly stimulated by 
IL-6. However, IL-6R also exists in a soluble form (sIL-6R) that is either produced by 
proteolytic cleavage of mIL-6R or by alternative splicing.10–13 sIL-6R can associate with 
free IL-6 and this complex is then recognized by the membrane-bound gp130, hence 
providing an alternative IL-6 signalling pathway available to cells that do not express 
mIL-6R, a process known as trans-signalling.7
The main genetic determinant of sIL-6R levels is thought to be the non-synonymous variant 
rs2228145 in exon 9,14 which maps to amino acid position 358 on the main cleavage site of 
IL-6R.15 Specifically, individuals that carry the Ala358 allele have increased sIL-6R 
levels14 – which in turn are associated with increased levels of allergic inflammation in the 
lung16 – and also increased risk of asthma.17 However, given that this variant explains ~19% 
of the variation in sIL-6R levels18 but the total heritability of this trait has been estimated at 
~70%,19 we hypothesised that additional variants in or near the IL6R gene contribute to 
sIL-6R variation independently of rs2228145 and may also influence asthma risk.
To test this hypothesis, in this study we (1) used data from the 1000 Genomes Project20 to 
comprehensively impute common variants in or near the IL6R gene; (2) tested these variants 
for association with sIL-6R levels measured in 360 individuals; (3) followed-up the most 
associated variants in an independent sample of 354 individuals; and (4) tested the replicated 
variants for association with IL6R transcript levels in two independent cohorts (N = 851 and 
5 191) and asthma risk (N = 47 514).
Results
Common variants affecting sIL-6R serum levels independently of rs4129267
To find new common variants associated with sIL-6R levels and possibly with asthma risk, 
we first measured sIL-6R serum levels in 360 asthmatics (Supplementary Table 1) who had 
been previously genotyped with Illumina 610K SNP arrays.17 sIL-6R measurements were 
performed in duplicate, with good agreement between assays (r = 0.95). Assay and plate 
effects explained 0.7% (P = 0.013) and 13.6% (P = 3.3×10−20), respectively, of the sample 
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variation in sIL-6R levels and so these effects were removed before association analyses. 
Duplicate measurements were then averaged and the overall distribution normalised using a 
rank-based inverse-normal transformation. There were no significant effects of age (P = 
0.256) or sex (P = 0.932) on sIL-6R levels.
The main genetic determinant of sIL-6R levels is thought to be the non-synonymous variant 
rs2228145,14 which is in high linkage disequilibrium (r2 = 0.99) with rs4129267 (Figure 1), 
a SNP that was directly genotyped in all individuals. We confirmed that the rs4129267 SNP 
has a significant impact on sIL-6R availability, increasing serum levels by 19.7 ng/ml for 
each copy of the T allele and explaining 30% of the interindividual variation (P = 1.8×10−29, 
Supplementary Figure 1). However, given that the heritability of sIL-6R levels has been 
estimated at ~70%,19 we hypothesised that additional variants in or near the IL6R gene 
contribute to variation in sIL-6R serum levels independently of rs4129267.
To test this hypothesis, we imputed 452 common variants in IL6R (± 50 kb) in the 360 
asthmatics using data from the 1000 Genomes Project as the reference panel. These variants, 
as well as 19 additional IL6R SNPs that were present in the Illumina 610K array, were then 
tested for association with sIL-6R levels, after adjustment for the effect of rs4129267. 
Association results for all 471 SNPs are included in Supplementary Table 2.
The variant with strongest association with rs4129267-adjusted sIL-6R levels was 
rs12083537 (uncorrected P = 0.0005, Supplementary Table 3 and Supplementary Figure 2); 
the association remained significant after correcting for the number of SNPs tested through 
100 000 permutations (P = 0.0496). The rs12083537 variant is in low linkage disequilibrium 
with rs4129267 (r2 = 0.03) and has a minor allele (G) frequency of 0.23. An additional three 
independent (r2 < 0.1) SNPs had a significant (uncorrected P < 0.05) association with 
sIL-6R levels after adjusting for both rs4129267 and rs12083537 (Supplementary Table 3). 
However, these associations did not remain significant after correction for multiple SNP 
testing (P > 0.05).
Replication of the new association between rs12083537 and sIL-6R serum levels
To confirm that the observed association between rs12083537 and sIL-6R levels was real 
and not a technical or statistical artefact, we performed a replication study using the same 
experimental procedure in an additional set of 354 unrelated asthmatics (Supplementary 
Table 4), genotyped for both rs4129267 and rs12083537.
After adjusting for the effects of rs4129267, rs12083537 was significantly associated with 
sIL-6R levels (P = 0.033), with the same direction of effect observed in the discovery 
analysis (Supplementary Figure 3). These results thus confirm that rs12083537 is a new 
quantitative trait locus for sIL-6R serum protein levels.
After combining data from the discovery and replication cohorts (combined N = 714), 
rs12083537 explained 2.2% of the variation in sIL-6R levels after adjustment for the effects 
of rs4129267 (P = 6.2×10−5). Before adjustment for rs4129267, rs12083537 explained 
0.15% of the variation in sIL-6R levels. The rs12083537:G minor allele decreased sIL-6R 
levels similarly in the three rs4129267 genotype classes (Figure 2).
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Association between rs12083537 with IL6R mRNA levels
The main genetic determinant of sIL-6R levels, rs2228145, is located on the main cleavage 
site of IL-6R and so it is thought to affect protein levels through a post-transcriptional 
mechanism.15 To provide some insight into the molecular mechanisms underlying the new 
rs12083537 association with sIL-6R protein levels, we investigated if this variant influenced 
IL6R mRNA levels measured in whole blood in a population-based study of adolescent 
twins and their relatives (N = 851). There was no significant association between 
rs12083537 and IL6R mRNA levels in this cohort, either measured by a probe targeting the 
3̘UTR (beta = −0.050 for the G allele, SE = 0.062, P = 0.4234) or exon 9 (beta = −0.062 for 
the G allele, SE = 0.063, P = 0.3209). On the other hand, we observed a significant 
association between rs4129267 (a proxy for rs2228145) and IL6R gene transcription (exon 9 
probe, beta = −0.120 for T allele, SE = 0.051, P = 0.0187). Counterintuitively, the 
rs4129267:T allele that increases sIL-6R protein levels was associated with decreased 
mRNA expression.
To confirm that the lack of association between rs12083537 and mRNA levels was not due 
to of low power or incomplete coverage of IL6R expression patterns, we performed a similar 
analysis in a larger independent study (N = 5 191) with IL6R gene expression levels in 
whole blood measured by 32 individual Affymetrix probes, targeting exons 5, 7, 8 and the 
3̘UTR. In this cohort, the rs12083537 variant was also not associated with IL6R 
transcription levels after a Bonferroni correction for the number of probes tested (P < 
0.0016, Supplementary Table 5). The strongest association was with a probe mapping to the 
3̘UTR region (P = 0.0031), with the rs12083537:A allele that increases sIL-6R protein 
levels being associated with decreased mRNA expression, as noted above for rs4129267.
Association between rs12083537 and asthma risk
The rs2228145:C (or rs4129267:T) allele that increases sIL-6R levels14 also increases 
asthma risk.17 We therefore tested the hypothesis that rs12083537 is also a genetic risk 
factor for asthma. Specifically, we hypothesised that, as for rs2228145, the rs12083537:A 
allele that is associated with higher sIL-6R levels would be predisposing for asthma. 
Association results were available for 47 514 individuals from three independent studies, 
including 16 705 doctor-diagnosed asthmatics and 30 809 controls. A consistent 
predisposing effect was observed for the rs12083537:A allele in all three studies (Table 1). 
Overall, the association between rs12083537 and asthma risk was weak but statistically 
significant (OR = 1.039, 95% C.I. = 1.002 – 1.078, P = 0.0419). Results remained largely 
unchanged when the association was tested while adjusting for rs4129267 (OR = 1.050, 95% 
C.I. = 1.012 – 1.089, P = 0.0088).
Discussion
We recently identified a variant (rs4129267) in the IL6R gene with a modest (OR = 1.09) but 
genome-wide significant association with asthma risk.17 This variant is in near complete LD 
with the exon 9 missense variant rs2228145, and is associated with a 1.4-fold increase in 
sIL-6R levels for each copy of the T allele.22 The goal of this study was to test the 
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hypotheses that (1) other variants in IL6R regulate gene expression and (2) that these also 
associate with asthma risk.
A single variant (rs12083537) located in intron 1 of IL6R, 2.9 kb away from exon 1, was 
found to associate with sIL-6R levels independently of rs4129267 and after correction for 
multiple SNP testing. A significant and consistent association for this variant was then 
observed in our replication panel. Furthermore, at the time of submission, we also noted that 
R. Ferreira et al.23 independently reported two new genetic associations for sIL-6R levels, 
one of which (rs1386821) is correlated with rs12083537 (r2 = 0.94). The alleles that increase 
sIL-6R levels for these two SNPs (rs12083537:A and rs1386821:T) are in phase and so our 
results are consistent with those of R. Ferreira et al. Together, these results establish 
rs12083537, or a variant in LD with it, as a new regulatory variant for sIL-6R serum levels.
The rs12083537 variant is located in a region with high H3K4Me1 lysine methylation in 
four cell lines, including lung fibroblasts and keratinocytes.24 This histone modification is 
associated with enhancers and promoters and so it is plausible that rs12083537 may 
influence gene transcription. However, analysis of mRNA levels extracted from whole blood 
in two independent cohorts did not identify any significant associations between rs12083537 
and IL6R transcription levels, after correcting for multiple testing. Thus, the molecular 
mechanism underlying the association between rs12083537 and sIL-6R levels remains to be 
elucidated. A potential caveat of our analysis was that we identified the association between 
rs12083537 and sIL-6R protein levels in asthma patients but then analysed mRNA levels in 
two studies that included mostly non-asthmatics. However, this difference is unlikely to 
explain the lack of association between rs12083537 and mRNA levels because IL6R 
regulatory variants have been shown to influence protein levels similarly in population-
based samples 22, healthy individuals 14, 25 and patients with different diseases 23, 25, 26. 
Gene expression studies in individual immune cell types or upon allergen stimulation may 
help characterise the function of this variant in greater detail.
Interestingly, we observed that the rs4129267:T allele that is associated with increased 
sIL-6R protein levels22 was associated with decreased IL6R mRNA levels, which may 
appear contradicting. The Illumina probe for which we observed an association with 
rs4129267 maps to exon 9 (containing the IL-6R trans-membrane domain), which is skipped 
in the main differentially spliced IL6R isoform that directly produces sIL-6R. Therefore, this 
probe measures the levels of the full length isoform, which necessarily decrease if splicing 
of exon 9 increases. Given that the rs4129267:T allele, or an allele associated with it (e.g. 
rs2228145:C), strongly increases the splicing of exon 9,23 it is in fact not surprising that 
consequently this allele is associated with decreased mRNA levels of the full length isoform. 
Unlike our results, R. Ferreira23 did not observe a significant effect of rs2228145 on the 
levels of the full length isoform. However, as the authors noted, splicing of exon 9 is a rare 
event. Therefore, the lack of association in that study likely reflected the low power 
provided by a small sample size (N = 88) to detect small differences in the levels of the full 
length isoform between genotype classes.
Lastly, we found rs12083537 to be significantly associated with asthma risk. Based on our 
analysis, each rs12083537:A allele increased sIL-6R serum levels by 2.4 ng/ml and 
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increased asthma risk by 1.04-fold. For comparison, each rs4129267:T allele increased 
sIL-6R serum levels by 19.7 ng/ml and increases asthma risk by 1.09-fold.17 The association 
between rs12083537 and asthma risk was consistent across the three cohorts analysed but 
only marginally statistically significant in the overall analysis. Replication of our results by 
well powered studies is therefore warranted; over 23 000 cases and 23 000 controls (or, for 
example, 18 000 cases and 36 000 controls) are required to achieve 80% power to detect (ř
= 0.05) the effect we observed.
In summary, our study demonstrates that at least two independent genetic variants influence 
sIL-6R serum levels. Consequently, pharmacogenetic studies of clinical response to 
tocilizumab, an anti-IL-6R monoclonal antibody approved to treat rheumatoid arthritis34 and 
suggested to treat asthma,16, 17 should consider the effects of not only the major genetic 
determinant of sIL-6R levels (rs2228145) but also of other confirmed regulatory variants 
such as rs12083537. For this purpose, multi-SNP scores that summarise an individual’s 
combined genetic risk of having high sIL-6R levels may prove useful.
Methods
Study participants
Genetic variants in or near the IL6R gene were tested for association with sIL-6R protein 
levels, mRNA levels and asthma risk in the cohorts described below. Informed consent was 
obtained from all participants and the study protocols were approved by the appropriate 
ethics committees.
Association with IL-6R protein levels – discovery cohort—To find new variants in 
the IL6R gene that affect sIL-6R levels, we first studied 360 unrelated asthmatic subjects 
from the 1995–1998 Asthma and Allergy study, which is described in detail elsewhere.27 
Briefly, 3 073 subjects were recruited from 802 families that were registered on the 
Australian Twin Registry and had at least one twin who previously reported a history of 
wheezing in studies conducted at QIMR and by collaborators elsewhere in Australia. 
Participants completed a questionnaire that was designed to validate the diagnosis of asthma 
and to obtain data on respiratory symptoms, environmental exposures and family history of 
asthma. In addition, participants underwent clinical testing, including lung function and skin 
prick tests. For the present study, we selected 360 unrelated individuals with available DNA 
and a serum sample, and who answered “Yes, told to me by a doctor” to the question “Have 
you ever had asthma?”. Demographics and clinical characteristics for this discovery sample 
are summarised in Supplementary Table 1. These individuals were included in a recent 
GWAS of asthma.17
Association with IL-6R protein levels – replication cohort—To confirm 
associations between SNPs and IL-6R protein levels observed in the discovery sample, we 
studied an additional sample of 354 unrelated asthmatics recruited through the QIMR 
Asthma Genetics Study between 2011 and 2013. In this study, individuals with a self-
reported doctor-diagnosis of asthma were recruited from the general community through 
media appeals (newspapers, radio, television and social media) to participate in a study of 
genetic risk factors for asthma. Participation included completing a brief online 
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questionnaire about asthma symptoms, medication and severity, and the provision of a blood 
sample for genetic and immune function testing. Blood was collected at a local pathology 
laboratory and shipped to QIMR by overnight courier. Demographics and clinical 
characteristics for this replication sample are summarised in Supplementary Table 4.
Association with IL6R mRNA levels—To provide some insight into the molecular 
mechanisms underlying SNP-protein associations, SNPs confirmed to associate with sIL-6R 
protein levels were then tested for association with mRNA levels measured in 851 
individuals from 262 families who participated in a genome-wide gene-expression study 
reported recently.28 Briefly, adolescent MZ and DZ twins, their siblings, and their parents 
have been recruited over a 21-year period into an ongoing study of the genetic and 
environmental factors influencing pigmented nevi and the associated risk of developing skin 
cancer and cognition (Twin Moles study)29. Results obtained in this cohort were confirmed 
by analysing expression levels from an additional 5 191 individuals who participated in two 
large-scale longitudinal studies: the Netherlands Twin Register (N = 3 170) and the 
Netherlands Study of Depression and Anxiety (N = 2 021); henceforth we refer to this as the 
NTR-NESDA eQTL study. The individual NTR and NESDA cohorts are described in detail 
elsewhere.30, 31
Association with asthma risk—SNPs associated with sIL-6R protein levels were also 
tested for association with asthma risk in 21 039 unrelated individuals of European ancestry 
who participated in two independent studies. First, 5 967 individuals who participated in the 
Australian asthma GWAS,17 including 2 110 doctor-diagnosed asthmatics and 3 857 
controls. Sample ascertainment and patient characteristics for this study are described in 
detail in Ferreira.17 Second, 15 072 customers of 23andMe, Inc., a personal genetics 
company, who had been genotyped as part of the 23andMe Personal Genome Service®. We 
selected 4 230 cases and 10 842 controls of European ancestry who had taken a survey about 
asthma. Cases (mean age 48, 54% female, 55% with onset of asthma at or before age 16) 
gave positive responses to the question “Have you ever been diagnosed by a doctor with 
asthma or bronchial asthma?”, and also checked a box indicating that they had ever had 
“allergic rhinitis (stuffed or dripping nose caused by allergies)”. Controls (mean age 49, 
39% females) gave negative responses to both questions. Association results from these 6 
340 cases and 14 699 controls were meta-analysed with publicly available results from 10 
365 asthmatics and 16 110 controls included in the GABRIEL GWAS,32 for a combined 
total sample size of 47 514 individuals, including 16 705 cases and 30 809 controls.
sIL-6R serum protein measurements
A 40 mL venous blood sample was collected from all consenting subjects. After spinning 10 
mL of blood in a serum tube at 805g for 10 min, the serum layer was extracted and stored at 
−80°C until analysis. ELISA kits (R&D Systems, Minneapolis, MN, USA) were used to 
measure sIL-6R levels according to manufacturer’s procedures. The optical density was 
determined using a PowerWave XS2 microplate spectrophotometer (BioTek Instruments, 
Inc.) at both 450 and 540 nm wavelengths. Results and standard curves were acquired with 
Gen5 2.0 Data Analysis Software. sIL-6R levels were measured in duplicate for each 
sample.
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IL6R mRNA measurements
Whole blood for expression profiling was collected from 851 individuals from the Twin 
Moles study and processed as described in detail by Powell et al.28 Briefly, total RNA was 
extracted from PAXgene™ tubes using the QIAGEN whole blood gene RNA purification 
kit. RNA quality and concentration was estimated with Agilent Bioanalyzer and 
subsequently converted to cDNA, amplified and purified using the Ambion Illumina 
TotalPrep RNA Amplification Kit (Ambion). Expression profiles were generated by 
hybridising 750 ng of cRNA to Illumina HumanHT-12 v4.0 Beadchip according to Illumina 
whole-genome gene expression direct hybridization assay guide (Illumina Inc, San Diego, 
USA). Beadchips were then washed and stained and subsequently scanned to obtain 
fluorescence intensities. Samples were scanned using an Illumina Bead Array Reader. 
Samples were randomised across chips and chip positions, with check for balance across 
families, sex and generation. For this study, we restricted our analysis to two probes 
targeting the IL6R gene, specifically ILMN_1754753 on the 3̘-end and ILMN_1696394 on 
exon 9 (Supplementary Table 6).
Gene expression association results were confirmed by analysing a further 5 191 individuals 
from the NTR-NESDA eQTL study. In this study, venous blood samples were drawn in the 
morning after an overnight fast; heparinised whole blood was transferred within 20 minutes 
of sampling into PAXgene™ tubes and stored at −20°C. RNA extraction and analysis was 
performed at the Rutgers University Cell and DNA Repository (USA). RNA was extracted 
using Qiagen Universal liquid handling system (PAXgene extraction kits following the 
manufacturer’s protocol). Total RNA was measured by spectroscopy (Trinean DropSense) 
to determine purity and concentration, while RNA fidelity was measured by the Agilent 
Bioanalyzer analysis. RNA samples were hybridized to Affymetrix U219 array plates 
(GeneTitan), which contains 530 467 probes, each 25 bases in length. Array hybridization, 
washing, staining, and scanning were carried out in an Affymetrix GeneTitan System 
following the manufacturer’s protocol. Non-uniquely mapping probes (hg19) and probes 
containing a polymorphic SNP based on snp137 (UCSC) were removed. Expression values 
were obtained using RMA normalization implemented in Affymetrix Power Tools (APT, v 
1.12.0). Thirty-two probes targeting IL6R were selected for analysis (Supplementary Table 
5).
IL6R SNP genotyping
For association with sIL-6R protein levels – discovery cohort—Genome-wide 
SNP data for the 360 individuals were obtained using Illumina 610-Quad Beadchip as part 
of the Australian Asthma Genetics Consortium GWAS, which is described in detail 
elsewhere.17 For this study, we selected 254 post-QC (minor allele frequency [MAF] > 1%, 
call rate > 95%, Hardy-Weinberg equilibrium P-value > 10−6) SNPs in or within 1 000 kb of 
IL6R, including rs4129267. To expand the genetic coverage of IL6R, these 254 directly 
genotyped SNPs were then used to impute 530 common variants (MAF >= 1%) from the 
1000 Genomes Project (March 2012 release, 1,092 samples of all ancestries) using 
Impute2.33 After QC (MAF > 1%, imputation information score > 0.3), there were 471 
SNPs located in or within 50 kb of IL6R available for analysis, of which 19 had been 
directly genotyped.
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For association with sIL-6R protein levels – replication cohort—Genotypes for 
two SNPs (rs4129267 and rs12083537) were obtained for the 354 individuals with 
Sequenom MassARRAY iPLEX platform; 12.5 ng of DNA isolated from buffy coats with a 
salt precipitation method were used per assay. SNP sequences were downloaded from the 
National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov/) and cross 
checked. Design of the PCR and iPLEX Extension assays was done using the Sequenom 
Design Suite (https://mysequenom.com/). The assays were then manually adjusted to 
increase the level of multiplexing. SNPs were typed using iPLEXTM Gold chemistry and 
analysed using a Sequenom MassARRAY Compact Mass Spectrometer (Sequenom Inc, San 
Diego, CA, USA). The PCR, SAP and iPLEX reactions were performed using half the 
volume of reagents recommended in the manufacturer’s specifications. The post-PCR 
products were spotted on a Sequenom SpectroChip 2, and the data was processed and 
analysed using Sequenom MassARRAY TYPER 4.0 software. The primers used to amplify 
both SNPs are included in Supplementary Table 7.
For association with IL6R mRNA levels—DNA samples from the Twin Moles study 
(N = 851) were genotyped by the Scientific Services Division at deCODE Genetics, Iceland, 
using the Illumina 610-Quad Beadchip. Genotypes were called with the Illumina 
BeadStudio software. Full details of genotyping procedures are given in Medland et al.34 
DNA extraction for the NTR-NESDA eQTL study (N = 5 191) has been described before.30 
Genotyping was performed on multiple SNP array platforms, including Perlegen 5.0, 
Illumina 370, Illumina 660, Illumina Omni Express 1M and Affymetrix 6.0. Standard pre-
imputation quality control filters were applied first within and then between chip platforms; 
subsequently, data were merged into a single dataset. Genome-wide SNP imputation was 
done with Impute2 33 using the 1000 Genomes phase I Interim Jun 2011 release. This 
included the rs12083537 variant analysed in this study, which was imputed with high 
confidence (information score > 0.9).
For association with asthma risk—We accessed individual-level genotype data for a 
single SNP (rs12083537) from the Australian GWAS (N = 5 967) and the 23andMe cohort 
(N = 15 072). This SNP was imputed in the Australian GWAS with high confidence 
(information score 0.97), using Impute2 and genotype data from the combined 1000 
Genomes (60 individuals with northern and western European ancestry from the Centre 
d’Etude du Polymorphisme Humain collection [CEU], March, 2010 release) and HapMap 3 
(955 individuals from 11 populations, February, 2009 release) projects as the reference 
panel. In the 23andMe cohort, rs12083537 was imputed with high confidence (r2 = 0.95) 
using the August 2010 release of the 1000 Genomes reference haplotypes.
Statistical analyses
QC of sIL-6R ELISA data—Each sample was measured in duplicate (two assays), with 
up to 80 serum samples included per ELISA plate. No outlier observations (located six 
standard deviations from the mean) were observed for either assay. The same procedure was 
used for the discovery and replication cohorts to estimate and remove the effects of both 
technical and biological effects on sIL-6R levels. Briefly, we (1) used linear regression to 
adjust for assay and plate effects; (2) normalized the distribution using a rank-based inverse-
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normal transformation; and (3) tested and, if significant (P < 0.05), adjusted for the effects 
of age and sex. Subsequent association analyses were carried out using the residuals 
obtained from (3).
Association analyses—Individual SNPs in IL6R, directly genotyped or imputed, were 
tested for association with sIL-6R protein levels (discovery and replication cohorts), mRNA 
levels and asthma risk. In all cases, we used additive allelic tests of association; for imputed 
SNPs, we used the inferred allelic dosage.
The association between the 471 SNPs in IL6R and protein levels was tested using linear 
regression in R. Association analyses were performed before and after adjusting sIL-6R 
levels for the effects of rs4129267, a SNP highly correlated with the missense variant 
rs2228145 (r2 = 0.99), the main genetic determinant of sIL-6R protein serum levels.22 To 
adjust for the effects of rs4129267, we (1) performed a linear regression of sIL-6R levels 
(dependent 410 variable) on rs4129267 allelic dosage (independent variable); (2) extracted 
the residuals from this analysis, which represent rs4129267-adjusted sIL-6R levels; and (3) 
performed a linear regression of rs4129267-adjusted sIL-6R levels (dependent variable) on 
the allelic dosage of individual SNPs (independent variable). To correct the observed 
asymptotic association P-value (Pobs) of a given SNP for the number of (and correlation 
between) SNPs tested, we (1) permuted rs4129267-adjusted sIL-6R levels between the 360 
asthmatics; (2) tested the permuted sIL-6R levels for association individually with each of 
the 471 SNPs and recorded the asymptotic P-value for the most significantly associated SNP 
(Pmin); (3) repeated steps (1) and (2) 100 000 times; and (4) calculated for each SNP the 
empirical association P-value corrected for the number of SNPs tested as the proportion of 
100 000 replicates for which Pmin ≤ Pobs.
Association with mRNA levels in the Twin Moles study was tested using 
MACH2QTL,35, 36 which takes into account the family structure of the data. In the NTR-
NESDA eQTL study, association with mRNA levels was tested using a linear mixed model 
to correct for family structure (as random effects) as well as sex, age, body mass index, 
smoking status, technical covariates and ancestry (as fixed effects).
Lastly, association with asthma risk was tested using logistic regression in R, including 
covariates to adjust for sample origin in the Australian GWAS and, in the 23andMe study, 
for age, sex and ancestry. Association analysis conditional on rs4129267 were performed in 
both studies by including this SNP (coded as allelic dosage: 0, 1 or 2) as a covariate in the 
logistic regression model. Only GWAS summary statistics were available for the GABRIEL 
study; as such, for this study, the conditional analysis was performed using the Yang et al 
approach implemented in GCTA.21 Fixed-effects meta-analysis of results from the 
Australian GWAS, 23andMe and the publicly available GABRIEL GWAS was performed 
with METAL.37
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Figure 1. Configuration of the interleukin-6 receptor gene (IL6R)
The promoter, exons (1 to 10) and 3̘UTR region are shown in grey boxes, while introns are 
shown as solid horizontal lines. Also highlighted are the locations of the main genetic 
regulator of sIL-6R levels (rs2228145), a commonly tested variant in LD with it 
(rs4129267), the novel regulatory variant identified in this study (rs12083537) and the two 
Illumina probes used to measure IL6R gene expression levels.
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Figure 2. sIL-6R serum levels as a function of rs4129267 and rs12083537 genotype (N = 714)
The association between sIL-6R levels (after adjusting for technical covariates) and 
rs12083537 genotype was tested using linear regression and is shown separately for each 
rs4129267 genotype class, including the proportion of variation in sIL-6R levels explained 
by rs12083537 (r2), the estimated regression coefficient (Ś) and the corresponding 
regression line.
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